Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference51 articles.
1. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089);Barlesi;J. Clin. Oncol.,2013
2. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma;Batchelor;J. Clin. Oncol.,2013
3. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation;Batchelor;Proc. Natl. Acad. Sci. U. S. A.,2013
4. Final results from the randomized phase II trial avareg (ML25739) with bevacizumab or fotemustine in recurrent GBM;Brandes;Neuro-Oncol.,2014
5. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger;Chauffert;Ann. Oncol.,2014
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06
2. Glioblastoma: Not Just Another Cancer;Cancer Discovery;2024-04-04
3. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma;ESMO Open;2024-04
4. Unraveling the Landscape of Pediatric Glioblastoma Biomarkers: A Comprehensive Review of Enhancing Diagnostics and Therapeutic Insights;Cureus;2024-03-30
5. Re-irradiation combined with bevacizumab in the treatment of glioblastoma recurrence;Siberian journal of oncology;2024-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3